Developmental and adult phenotyping directly from mutant embryonic stem cells

  1. Sophia H. L. George*,,
  2. Marina Gertsenstein*,
  3. Kristina Vintersten*,
  4. Ella Korets-Smith*,,
  5. John Murphy,
  6. Mary E. Stevens,
  7. Jody J. Haigh*,§, and
  8. Andras Nagy*,,
  1. *Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, ON, Canada M5G 1X5;
  2. Department of Molecular and Medical Genetics, University of Toronto, Toronto, ON, Canada M5S 1A8; and
  3. Bayer Corporation, 800 Dwight Way, P.O. Box 1986, Berkeley, CA 94701
  1. Edited by John B. Gurdon, University of Cambridge, Cambridge, United Kingdom, and approved January 8, 2007 (received for review October 20, 2006)

Abstract

Tetraploid embryo complementation assay has shown that mouse ES cells alone are capable of supporting embryonic development and adult life of mice. Newly established F1 hybrid ES cells allow the production of ES cell-derived animals at a high enough efficiency to directly make ES cell-based genetics feasible. Here we report the establishment and characterization of 12 new F1 hybrid ES cell lines and the use of one of the best (G4) in a gain- and loss-of-function genetic study, where the in vivo phenotypes were assessed directly from ES cell-derived embryos. We found the generation of G4 ES cell-derived animals to be very efficient. Furthermore, even after two consecutive rounds of genetic modifications, the majority of transgenic lines retained the original potential of the parental lines; with 10–40% of chimeras producing ES cell-derived animals/embryos. Using these genetically altered ES cells, this success rate, in most cases, permitted the derivation of a sufficient number of mutants for initial phenotypic analyses only a few weeks after the establishment of the cell lines. Although the experimental design has to take into account a moderate level of uncontrolled damage on ES cell lines, our proof-of-principle experiment provides useful data to assist future designs harnessing the power of this technology to accelerate our understanding of gene function.

Footnotes

  • To whom correspondence should be addressed. E-mail: nagy{at}mshri.on.ca
  • Author contributions: S.H.L.G., M.E.S., J.J.H., and A.N. designed research; S.H.L.G., M.G., K.V., E.K.-S., and J.J.H. performed research; J.M. and A.N. contributed new reagents/analytic tools; S.H.L.G. and A.N. analyzed data; S.H.L.G. and A.N. wrote the paper; S.H.L.G. generated all transgenic ES lines and performed phenotypic analyses; and M.G. derived F1 hybrid ES cell lines.

  • §Present address: Department of Molecular Biomedical Research, Flanders Institute for Biotechnology and Ghent University, B-9052 Ghent, Belgium.

  • The authors declare no conflict of interest.

  • This article is a PNAS direct submission.

  • This article contains supporting information online at www.pnas.org/cgi/content/full/0609277104/DC1.

  • Abbreviations:
    GOI,
    gene of interest;
    En,
    embryonic day n.
« Previous | Next Article »Table of Contents